T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis
NCT01078337 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15
Last updated 2010-03-02
Summary
To determine if MRD (minimal residual disease) can be found in the blood (only) as opposed to bone marrow in children with ALL (acute lymphoblastic leukemia).
Conditions
- Leukemia, Lymphocytic, Acute
Interventions
- PROCEDURE
-
bone marrow aspiration
- PROCEDURE
-
peripheral blood sampling
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Gary V Dahl · Stanford University
Eligibility
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-11-30
- Primary Completion
- 2007-10-31
- Completion
- 2007-10-31
Countries
- United States
Study Locations
More Related Trials
-
Studying Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01581528 ·Status: COMPLETED
-
Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
NCT01245231 ·Status: COMPLETED
-
Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial
NCT01629745 ·Status: COMPLETED
-
MRD Detection by NGS in Pediatric B-ALL
NCT05973032 ·Status: COMPLETED
-
Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients
NCT03488862 ·Status: COMPLETED
-
Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes
NCT03621241 ·Status: RECRUITING
-
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
NCT03846362 ·Status: UNKNOWN ·Phase: PHASE3
-
Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes
NCT03363399 ·Status: COMPLETED
-
Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)
NCT07269067 ·Status: NOT_YET_RECRUITING
-
Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
NCT06452732 ·Status: RECRUITING
-
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
NCT07270978 ·Status: RECRUITING ·Phase: PHASE1
-
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
NCT02795520 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
NCT07012044 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
NCT05788679 ·Status: RECRUITING ·Phase: PHASE2
-
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT01898793 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of GDX012 in Patients With MRD Positive AML
NCT05001451 ·Status: TERMINATED ·Phase: PHASE1
-
Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
NCT05940961 ·Status: RECRUITING ·Phase: PHASE2
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes.
NCT04399018 ·Status: ACTIVE_NOT_RECRUITING
-
Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission
NCT00458523 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT00801489 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Assess an Interphase Cycle With Flotetuzumab.
NCT05063123 ·Status: WITHDRAWN ·Phase: PHASE2
-
Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
NCT01321385 ·Status: COMPLETED
-
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
NCT03739606 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)
NCT02185781 ·Status: COMPLETED ·Phase: PHASE1